MINI FUTURE LONG - NOVO-NORDISK B | Real-time Euronext Paris 10:17:45 2024-07-12 am EDT | ||
| 4.875 EUR | +3.39% |
|
| Current month | -11.12% | ||
| 1 month | -7.09% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 4.875 | +3.39% |
| 24-07-11 | 4.715 | -4.26% |
| 24-07-10 | 4.925 | +2.07% |
| 24-07-09 | 4.825 | -4.55% |
| 24-07-08 | 5.055 | +2.85% |
Real-time Euronext Paris
Last update July 12, 2024 at 10:17 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| O3UNB | |
| ISIN | FRBNPP06FS58 |
| Date issued | 2024-02-02 |
| Strike | 614.2 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.51 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.655 € |
|---|---|
| Lowest since issue | 2.395 € |
| Spread | 0.01 € |
| Spread % | 0.20% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
967.3
DKK
Average target price
956.5
DKK
Spread / Average Target
-1.11%
- Stock Market
- Certificates
- O3UNB Certificat
